Nuvo Research Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jef saunders who wrote (7477)	7/4/2001 7:02:28 AM
From: Mark Bartlett	Read Replies (1) of 14101

Jef, Technically, the administrator of the trial should have no way of knowing if the patient was getting WF10 or placebo. She had to be guessing the patient was getting WF10 due to the difference in the outcome between this patient, and what she was use to seeing with patients at that stage of disease. She would, of course, also have known the results of the phase II study, so it would not be difficult to put the pieces together. The only other explanation is the patient was knowingly moved to the WF10 arm for compassionate reasons. MB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next